MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
MIMEDX Group, Inc. (Nasdaq: MDXG) highlighted a New York Times article on placental allografts for treating hard-to-heal, acute, and chronic wounds. The article, titled 'Her Face Was Unrecognizable After an Explosion. A Placenta Restored It,' emphasizes the benefits of placental allografts in various wound care and surgical procedures. It also raises awareness about the opportunity for mothers to donate placentas after healthy C-section deliveries, which MIMEDX uses to produce most of its products.
The article features two patients from MIMEDX's 'Patient Story' series, showcasing their remarkable recoveries using the company's products. MIMEDX CEO Joseph H. Capper believes this article, along with a recent Nature – Scientific Reports publication, will increase awareness about the unique properties and growing clinical use of placental-derived products for treating chronic and hard-to-heal wounds.
MIMEDX Group, Inc. (Nasdaq: MDXG) ha evidenziato un articolo del New York Times sugli allografi placentari per il trattamento di ferite acute e croniche difficili da guarire. L'articolo, intitolato 'Il suo volto era irriconoscibile dopo un'esplosione. Una placenta l'ha ripristinato,' sottolinea i benefici degli allografi placentari in vari interventi di cura delle ferite e chirurgici. Inoltre, sensibilizza sull'opportunità per le madri di donare placente dopo parti cesarei sani, che MIMEDX utilizza per produrre la maggior parte dei suoi prodotti.
L'articolo presenta due pazienti della serie 'Storia dei Pazienti' di MIMEDX, mostrando le loro straordinarie guarigioni grazie all'uso dei prodotti dell'azienda. Il CEO di MIMEDX, Joseph H. Capper, crede che questo articolo, insieme a una recente pubblicazione su Nature – Scientific Reports, aumenterà la consapevolezza riguardo alle proprietà uniche e all'uso clinico crescente dei prodotti derivati dalla placenta per il trattamento di ferite croniche e difficili da guarire.
MIMEDX Group, Inc. (Nasdaq: MDXG) destacó un artículo del New York Times sobre aloinjertos de placenta para el tratamiento de heridas agudas y crónicas difíciles de sanar. El artículo, titulado 'Su rostro era irreconocible después de una explosión. Una placenta lo restauró,' enfatiza los beneficios de los aloinjertos de placenta en varios procedimientos de cuidado de heridas y quirúrgicos. También aumenta la conciencia sobre la oportunidad para las madres de donar placentas después de partos por cesárea saludables, las cuales MIMEDX utiliza para producir la mayor parte de sus productos.
El artículo presenta a dos pacientes de la serie 'Historia de Pacientes' de MIMEDX, mostrando sus notables recuperaciones utilizando los productos de la empresa. Joseph H. Capper, CEO de MIMEDX, cree que este artículo, junto con una reciente publicación de Nature – Scientific Reports, aumentará la conciencia sobre las propiedades únicas y el creciente uso clínico de los productos derivados de la placenta para tratar heridas crónicas y difíciles de sanar.
MIMEDX 그룹, Inc. (Nasdaq: MDXG)는 어려운 상처 치료를 위한 태반 동종 이식에 대한 뉴욕 타임스 기사를 강조했습니다. '폭발 후 그녀의 얼굴은 알아볼 수 없었다. 태반이 그것을 회복시켰다'라는 제목의 이 기사는 다양한 상처 치료 및 외과 절차에서 태반 동종 이식의 이점을 강조합니다. 또한 건강한 제왕절개 출산 후 어머니들이 태반을 기증할 기회를 알리고 있으며, MIMEDX는 이를 통해 대부분의 제품을 생산합니다.
이 기사는 MIMEDX의 '환자 이야기' 시리즈에 등장하는 두 명의 환자를 소개하며, 회사의 제품을 사용하여 그들의 놀라운 회복을 보여줍니다. MIMEDX의 CEO인 Joseph H. Capper는 이 기사와 최근의 Nature – Scientific Reports의 출판물이 만성 및 치유가 어려운 상처에 대한 태반 유래 제품의 독특한 특성과 증가하는 임상 사용에 대한 인식을 높일 것이라고 믿고 있습니다.
MIMEDX Group, Inc. (Nasdaq: MDXG) a mis en avant un article du New York Times concernant les allogreffes de placenta pour traiter les blessures aiguës et chroniques difficiles à guérir. L'article, intitulé 'Son visage était méconnaissable après une explosion. Un placenta l'a restauré,' souligne les avantages des allogreffes de placenta dans divers soins des blessures et procédures chirurgicales. Il sensibilise également sur l'opportunité pour les mères de faire don de placentas après des césariennes saines, que MIMEDX utilise pour produire la plupart de ses produits.
L'article présente deux patients de la série 'Histoire de Patients' de MIMEDX, mettant en avant leurs remarquables guérisons par l'utilisation des produits de l'entreprise. Le PDG de MIMEDX, Joseph H. Capper, croit que cet article, en conjonction avec une récente publication dans Nature – Scientific Reports, augmentera la sensibilisation concernant les propriétés uniques et l'utilisation clinique croissante des produits dérivés du placenta pour traiter les blessures chroniques et difficiles à guérir.
MIMEDX Group, Inc. (Nasdaq: MDXG) hob einen Artikel der New York Times über plazentare Allografts zur Behandlung von schwer heilbaren, akuten und chronischen Wunden hervor. Der Artikel mit dem Titel 'Ihr Gesicht war nach einer Explosion unrecognizable. Eine Plazenta stellte es wieder her' hebt die Vorteile plazentare Allografts in verschiedenen Wundversorgung und chirurgischen Verfahren hervor. Er sensibilisiert auch für die Möglichkeit für Mütter, Plazenten nach gesunden Kaiserschnittgeburten zu spenden, die MIMEDX zur Herstellung der meisten seiner Produkte verwendet.
Der Artikel features zwei Patienten aus der 'Patientengeschichte'-Reihe von MIMEDX, die ihre bemerkenswerte Genesung unter Verwendung der Produkte des Unternehmens zeigen. Joseph H. Capper, der CEO von MIMEDX, glaubt, dass dieser Artikel zusammen mit einer aktuellen Veröffentlichung der Nature – Scientific Reports das Bewusstsein für die einzigartigen Eigenschaften und die zunehmende klinische Anwendung plazentär abgeleiteter Produkte zur Behandlung von chronischen und schwer heilbaren Wunden erhöhen wird.
- Increased public awareness of placental allografts through New York Times article
- MIMEDX products featured in patient success stories
- Potential for increased interest in placental donation after C-section deliveries
- None.
Story Featured Patients Treated with MIMEDX Products
MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today’s New York Times: “Her Face Was Unrecognizable After an Explosion. A Placenta Restored It.”
The author underscored the benefits of placental allografts for a variety of wound care and surgical procedures and brought attention to the largely unknown opportunity for a mother to donate her nutrient rich placenta after a healthy C-section delivery. MIMEDX uses this source material to produce the majority of its product offerings today.
Commenting on the article, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, “We were delighted to see attention called to this area of patient care and to contribute to this important piece. While MIMEDX is not mentioned by name, two individuals from our “Patient Story” series, Marcella and Phyllis, are prominently featured in the article, showcasing their remarkable recoveries. In both cases our products played a central role.”
Mr. Capper concluded, “We believe this article and the recently-published Nature – Scientific Reports publication will increase awareness about the unique scientific properties and growing clinical use of placental-derived products to treat patients with chronic and other hard-to-heal wounds.”
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
FAQ
What was the New York Times article about MDXG's placental allografts?
How does MIMEDX (MDXG) source material for its placental allograft products?
What impact does MIMEDX (MDXG) expect from the New York Times article on placental allografts?
